Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Understanding Your Complete Blood Count
- This document helps aims at educating about complete blood count. A complete blood count, often referred to as a CBC, is a common blood test. A CBC provides detailed information about three types of cells in your blood: red blood cells, white blood cells, and platelets. These blood cells are...
- White papers 2001-03-01
Additional Resources
- Blood Substitute Found Safe in Large Phase III Trial
- A blood substitute product called HBOC-201 proved safe and effective in a six-week Phase III multi-center clinical trial, a new study reports. In all, 688 patients, ages 18 and older, who had elective orthopedic surgery initially received either one unit of blood about one pint or an equivalent one...
- Articles 2008-06-20
- Health Tip: Reduce Your Risk of Anemia
- Anemia occurs when there aren't enough red blood cells in your blood, or they are deficient in a protein called hemoglobin. This means your red blood cells don't carry enough oxygen to the rest of the body. Women and people with chronic disease are at greater risk of becoming anemic....
- Articles 2008-06-19
- U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure®
- CAMBRIDGE, Mass., June 18 /PRNewswire-FirstCall/ -- Biopure Corporation announced today that the U.S. Naval Medical Research Center NMRC has submitted a new protocol for review by the Food and Drug Administration FDA for a Phase 2 clinical trial of HemopureR [hemoglobin glutamer - 250 bovine], or HBOC-201, for...
- Articles 2008-06-18
- Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
- MONTREAL, June 14 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week. Dr. Lyne Gagnon,...
- Articles 2008-06-14
- Positive Clinical Data for PBI-1402 Presented at the Annual Congress of the European Hematology Association
- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week. Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data on PBI-1402...
- Articles 2008-06-14
- Sangart Responds to Report Published in the Journal of the American Medical Association and Provides Update on Phase III Trials of Hemospan®
- SAN DIEGO, June 11 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, today issued the following statement in response to a report in the May 21st edition of the Journal of the American Medical Association JAMA linking...
- Articles 2008-06-11
- Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks
- Qnexa Subjects Had Weight Loss of 8.0 Percent and Significant Improvement in Cardiovascular Risk Factors MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced the positive results of OB-202, a 28-week, phase 2 clinical...
- Articles 2008-06-10
- Biopure Responds to JAMA and Meta-Analysis
- CAMBRIDGE, Mass., June 9 /PRNewswire-FirstCall/ -- Biopure Corporation today announced that it has sent an open letter to the editors of the Journal of the American Medical Association JAMA. The letter asks for a retraction of the meta-analysis and the accompanying editorial that appeared on line on...
- Articles 2008-06-09
- US blacks' diabetes care results 'less ideal' than for whites: study
- WASHINGTON AFP — Even when they are cared for by the same doctor, black Americans who suffer from diabetes are less likely than their white counterparts to bring the illness under control, a study released Monday showed. Researchers from Harvard Vanguard Medical Associates analysed electronic medical records from...
- Articles 2008-06-09
- Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-On Therapy Studies
- Results from five pivotal phase 3 studiesof alogliptin were announced today at the American Diabetes AssociationADA 68th Scientific Sessions by Takeda Global Research & DevelopmentCenter, Inc. Alogliptin, which has been shown to be a highly selectiveinhibitor of dipeptidyl peptidase-4 (DPP-4), is currently underinvestigation as an oral treatment for type...
- Articles 2008-06-07
- DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
- Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than Hemoglobin A1C of Exenatide, Sitagliptin, Pramlintide and Prandial Insulin Therapies in Certain Diabetic Populations SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today results from the ongoing DURABLE clinical trial showing that the GlycoMark blood...
- Articles 2008-06-07
- Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
- Data from five pivotal phase 3 studies presented at the American Diabetes Association 68th Scientific Sessions SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association ADA 68th Scientific Sessions by Takeda Global Research...
- Articles 2008-06-07
- ONGLYZA™ Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes
- SAN FRANCISCO -- Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions in key...
- Articles 2008-06-07
- Biopure Announces MHRA Meeting Update
- CAMBRIDGE, Mass., June 5 /PRNewswire-FirstCall/ -- Biopure Corporation announced today an update regarding a meeting with the Medicines and Healthcare products Regulatory Agency MHRA addressing the Company's pending application for marketing authorization for HemopureR [hemoglobin glutamer - 250 bovine]. The meeting, held on May 29, was...
- Articles 2008-06-05
- VIVUS Announces the Podium Presentation of Phase 2 Data for Qnexa in Type 2 Diabetics at the American Diabetes Association Meeting
- VIVUS to Host Investor Event and Webcast Following ADA Presentation to Discuss Results of OB-202 MOUNTAIN VIEW, Calif. -- VIVUS, Inc (NASDAQ: VVUS) a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that the results from OB-202, a 28-week, placebo controlled, safety...
- Articles 2008-06-04
- Noninvasive hemoglobin testing
- The Masimo Radical-7 Pulse-Oximeter is the first device to noninvasively and continuously measure hemoglobin SpHb and oxygen content SpOC both pending FDA clearance, carboxyhemoglobin SpCO, methemoglobin SpMet and pleth variability index PVI, in addition to oxyhemoglobin (Sp[O.sub.2]), perfusion index PI and pulse rate. Previous methods for testing hemoglobin were invasive,...
- Articles 2008-06-01
- Advances in neonatal hematology
- Advances in neonatal hematology. Wiwanitkit, Viroj. Nova Biomedical Books 2007 201 pages $129.00 Hardcover RJ269 Erythropoiesis starts in utero and neonates are born with a complete adult system, but the switch from alpha-globin to...
- Articles 2008-06-01
- Splenic rupture and malignant Mediterranean spotted fever
- To the Editor: Mediterranean spotted fever MSF is a Rickettsia conorii infection endemic to the Mediterranean. In this case, a 55-year-old man was referred to the Necker-Enfants Malades Hospital, Paris, France, for fever, myalgia, and hypotensive shock. The patient had been in Southern France Montpellier 6 days before symptom onset...
- Articles 2008-06-01
- Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
- CHICAGO, May 30 /PRNewswire/ -- Data from three observational studies reported at the American Society of Clinical Oncology ASCO Annual Meeting evaluated transfusion-related outcomes in cancer chemotherapy patients with various hemoglobin Hb levels prior to or during administration of erythropoiesis-stimulating agents ESAs. Two analyses were conducted using...
- Articles 2008-05-30
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Create new ways to live, work and play with Intel
-
Learn how Intel researchers around the world are developing with tera-scale computing, wireless computing anywhere on earth, advanced exploratory research, and more.
- Learn about new technology that improves every facet of life >>
- THE FUTURE JUST LOST ITS LEAD.
-
We're relentless about invention. Our latest technology includes hafnium-based circuitry, mobile technology for a new generation of MIDs, and 32 nanometer processing.
- Learn more >>
- Revolutionary Manufacturing
-
Get inside Intel's advanced manufacturing processes, including research and development, wafer fabrication, and boards and semi-conductor manufacturing.
- Read how Intel is precision tuning fast, smart, more energy-efficient technologies >>
